Evonik launches recombinant collagen Vecollan® for use in clinical studies
Essen, Germany. Evonik’s Vecollan® recombinant, non-animal-derived collagen-like protein platform is now available in a grade suitable for use in clinical trials. The new grade marks a significant process scale-up milestone for this new biomaterial, supporting the development of medical devices that improve safety and performance for patients. The new clinical-grade Vecollan® is an innovation in…
